/
/
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Chapters
- 00:04Title
- 01:19Rapamycin Preparation in Poly (l-lactide)-poly (epsilon-caprolatcone) (PLLA-PCL)
- 01:56Rapamycin-Eluting PLLA-PCL Murine Airway Stent Creation
- 03:08Laryngotracheal Stenosis Induction
- 04:50Transoral PLLA-PCL Stent Placement
- 05:45Histologic Sample Preparation
- 06:26Results: Representative Tracheal Stent Biocompatibility Assessment
- 07:23Conclusion
Laryngotracheal stenosis results from pathologic scar deposition that critically narrows the tracheal airway and lacks effective medical therapies. Using a PLLA-PCL (70% poly-L-lactide and 30% polycaprolactone) stent as a local drug delivery system, potential therapies aimed at decreasing scar proliferation in the trachea can be studied.
